Integra LifeSciences Holdings (IART) - Total Assets
Based on the latest financial reports, Integra LifeSciences Holdings (IART) holds total assets worth $3.65 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IART net assets for net asset value and shareholders' equity analysis.
Integra LifeSciences Holdings - Total Assets Trend (1995–2024)
This chart illustrates how Integra LifeSciences Holdings's total assets have evolved over time, based on quarterly financial data.
Integra LifeSciences Holdings - Asset Composition Analysis
Current Asset Composition (December 2024)
Integra LifeSciences Holdings's total assets of $3.65 Billion consist of 26.8% current assets and 73.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.1% |
| Accounts Receivable | $272.37 Million | 6.8% |
| Inventory | $429.09 Million | 10.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.21 Billion | 29.9% |
| Goodwill | $1.10 Billion | 27.2% |
Asset Composition Trend (1995–2024)
This chart illustrates how Integra LifeSciences Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Integra LifeSciences Holdings.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integra LifeSciences Holdings's current assets represent 26.8% of total assets in 2024, a decrease from 47.9% in 1995.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2024, down from 23.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 56.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 29.9% of total assets.
Integra LifeSciences Holdings Competitors by Total Assets
Key competitors of Integra LifeSciences Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Integra LifeSciences Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.14 | 1.20 | 3.09 |
| Quick Ratio | 1.80 | 0.73 | 2.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $779.53 Million | $186.96 Million | $836.19 Million |
Integra LifeSciences Holdings - Advanced Valuation Insights
This section examines the relationship between Integra LifeSciences Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.82 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 6.8% |
| Total Assets | $4.04 Billion |
| Market Capitalization | $851.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Integra LifeSciences Holdings's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Integra LifeSciences Holdings's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Integra LifeSciences Holdings (1995–2024)
The table below shows the annual total assets of Integra LifeSciences Holdings from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.04 Billion | +6.75% |
| 2023-12-31 | $3.78 Billion | -2.77% |
| 2022-12-31 | $3.89 Billion | +2.84% |
| 2021-12-31 | $3.78 Billion | +4.63% |
| 2020-12-31 | $3.62 Billion | +9.44% |
| 2019-12-31 | $3.30 Billion | +6.29% |
| 2018-12-31 | $3.11 Billion | -3.22% |
| 2017-12-31 | $3.21 Billion | +77.62% |
| 2016-12-31 | $1.81 Billion | +1.87% |
| 2015-12-31 | $1.77 Billion | +12.42% |
| 2014-12-31 | $1.58 Billion | +31.97% |
| 2013-12-31 | $1.20 Billion | +2.80% |
| 2012-12-31 | $1.16 Billion | +1.70% |
| 2011-12-31 | $1.14 Billion | +12.46% |
| 2010-12-31 | $1.02 Billion | +8.21% |
| 2009-12-31 | $940.10 Million | -9.12% |
| 2008-12-31 | $1.03 Billion | +26.46% |
| 2007-12-31 | $818.01 Million | +33.31% |
| 2006-12-31 | $613.62 Million | +36.84% |
| 2005-12-31 | $448.43 Million | -1.81% |
| 2004-12-31 | $456.71 Million | +10.71% |
| 2003-12-31 | $412.53 Million | +50.19% |
| 2002-12-31 | $274.67 Million | +20.69% |
| 2001-12-31 | $227.59 Million | +163.06% |
| 2000-12-31 | $86.51 Million | +30.49% |
| 1999-12-31 | $66.30 Million | +91.07% |
| 1998-12-31 | $34.70 Million | -9.64% |
| 1997-12-31 | $38.40 Million | -21.15% |
| 1996-12-31 | $48.70 Million | +151.03% |
| 1995-12-31 | $19.40 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural r… Read more